Drug Trial Radar · NCT04375033
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
952
Planned (sponsor's estimate)
Start
Nov 3, 2020
Primary completion
Sep 30, 2028
Study completion May 31, 2029
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300 milligrams (mg) is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Conditions
- Opioid Use Disorder
Interventions
Sublingual buprenorphine with naloxoneDrug
The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.
Injectable subcutaneous buprenorphineDrug
Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously at each 28-day visit through Week 48.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Retention in Treatment ChangeTime frame: Approximately every 4 weeks until the first period of missed prescription medication coverage lasting at least 4 weeks through week 52
- Opioid AbstinenceTime frame: Approximately every 2 weeks through 52 weeks (active phase) and via EMR review for up to 10 years (passive phase)
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama · Terminated
Phoenix VA Health Care System, Phoenix, AZ
Phoenix, Arizona · Recruiting
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California · Recruiting
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California · Recruiting
San Francisco VA Medical Center, San Francisco, CA
San Francisco, California · Recruiting
CERC (VISN1, West Haven, CT)
West Haven, Connecticut · Recruiting
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut · Active not recruiting
Wilmington VA Medical Center, Wilmington, DE
Wilmington, Delaware · Recruiting
Bay Pines VA Healthcare System, Pay Pines, FL
Bay Pines, Florida · Recruiting
North Florida/South Georgia Veterans Health System, Gainesville, FL
Gainesville, Florida · Recruiting
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts · Terminated
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota · Terminated
Louis Stokes VA Medical Center, Cleveland, OH
Cleveland, Ohio · Terminated
Dayton VA Medical Center, Dayton, OH
Dayton, Ohio · Recruiting
Philadelphia MultiService Center, Philadelphia, PA
Philadelphia, Pennsylvania · Recruiting
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Pittsburgh, Pennsylvania · Terminated
Providence VA Medical Center, Providence, RI
Providence, Rhode Island · Terminated
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Dallas, Texas · Recruiting
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah · Recruiting
White River Junction VA Medical Center, White River Junction, VT
White River Junction, Vermont · Terminated
Hampton VA Medical Center, Hampton, VA
Hampton, Virginia · Recruiting
Salem VA Medical Center, Salem, VA
Salem, Virginia · Recruiting
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington · Recruiting
Huntington VA Medical Center, Huntington, WV
Huntington, West Virginia · Recruiting
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.